CSS
STOK icon

Cubist Systematic Strategies’s Stoke Therapeutics STOK Stock Holding History

Cubist Systematic Strategies’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-28,876
Closed -$241K – 4275
2023
Q1 		$241K Sell
28,876
-20,100
-41% -$181K ﹤0.01% 3129
2022
Q4 		$452K Buy
48,976
+34,340
+235% +$357K ﹤0.01% 3094
2022
Q3 		$188K Sell
14,636
-27,092
-65% -$432K ﹤0.01% 3801
2022
Q2 		$551K Sell
41,728
-3,116
-7% -$47.3K ﹤0.01% 2990
2022
Q1 		$944K Buy
44,844
+33,131
+283% +$663K 0.01% 2071
2021
Q4 		$281K Sell
11,713
-320
-3% -$7.64K ﹤0.01% 2843
2021
Q3 		$306K Buy
12,033
+1,451
+14% +$40.5K ﹤0.01% 2345
2021
Q2 		$356K Buy
10,582
+4,416
+72% +$156K ﹤0.01% 2229
2021
Q1 		$239K Buy
+6,166
New +$351K ﹤0.01% 2372

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Cubist Systematic Strategies's STOK Position: Q2 2023 in Review

Cubist Systematic Strategies sold out of Stoke Therapeutics (STOK) in Q2 2023, closing a stake of 28,876 shares — an estimated $241K sold.

Cubist Systematic Strategies first reported a position in STOK in Q1 2021 and held it in 9 quarters. The position peaked at $944K in Q1 2022. 100 funds tracked by Wall St. Rank hold STOK as of Q2 2023.

  • Cubist Systematic Strategies reported no remaining Stoke Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 28,876 Stoke Therapeutics shares in Q2 2023, an estimated $241K.
  • Cubist Systematic Strategies first reported a position in Stoke Therapeutics in Q1 2021 and held it in 9 quarters.
  • Cubist Systematic Strategies's Stoke Therapeutics position peaked at $944K in Q1 2022.
  • 100 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2023.

Based on Cubist Systematic Strategies's 13F filing for Q2 2023, filed 14 Aug 2023.